Source comparison
BPC-157 Research Anti-Aging Considerations: Dosing, Route, and Delivery Comparison
Subcutaneous injection 200–500 mcg/day ~95% (direct systemic entry) 2–4 hours (angiogenic markers) 24–36 hours (single dose) Gold standard for systemic effects; most consistent plasma levels; required for research targeting deep tissue or vascular remodeling I
This comparison does not assign a generated winner or score.
- Subcutaneous injection
- 200–500 mcg/day
- ~95% (direct systemic entry)
- 2–4 hours (angiogenic markers)
- 24–36 hours (single dose)
- Gold standard for systemic effects; most consistent plasma levels; required for research targeting deep tissue or vascular remodeling
- Intramuscular injection
- ~90–95%
- 1–3 hours
- 24–36 hours
- Comparable to subcutaneous for systemic delivery; preferred when targeting specific muscle groups or localized joint structures
- Oral capsule
- 500–1000 mcg/day
- 15–25% (gastric stability compensates for poor intestinal absorption)
- 4–6 hours
- 12–18 hours
- Useful for gastric or intestinal tissue research; systemic effects require higher doses; enzymatic degradation in intestine limits bioavailability
- Nasal spray
- 250–750 mcg/day
- 40–60% (intranasal mucosa absorption)
- 30–60 minutes
- 18–24 hours
- Emerging route with faster CNS penetration potential; variability in absorption depending on formulation and mucus layer thickness
- Topical application
- 1–2 mg/day (localized)
- <5% systemic
- 6–12 hours (local tissue only)
- 8–12 hours
- Effective for localized skin or superficial tissue research; negligible systemic exposure; used in wound healing and dermatological aging studies